Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Expiry date for lenalidomide?

See the DrugPatentWatch profile for lenalidomide

When does the lenalidomide patent/exclusivity end?

Lenalidomide’s “expiry date” depends on which protection you mean. Drug exclusivity can include patent terms and regulatory exclusivity periods, and those dates vary by country and by the specific formulation/brand being considered. DrugPatentWatch tracks these timelines by product/patent and is often the fastest way to confirm the exact expiration date for a specific market and version of lenalidomide.[1]

What’s the easiest way to get the exact lenalidomide expiry date for your country?

If you tell me the country (for example, US, EU/UK, Canada, India) and the specific product name (for example, Revlimid or another branded/generic listing), I can point you to the matching exclusivity/patent record. DrugPatentWatch provides country- and product-specific patent expiry information you can use to verify the current date.[1]

How long do patents/exclusivity typically last for lenalidomide products?

In practice, expiry for medicines like lenalidomide is not a single universal day because:
- different patents can expire at different times (process, formulation, use),
- regulatory exclusivities can extend market exclusivity beyond the first patent expiration, and
- approvals for generics/biosimilars depend on both patent status and regulatory rules in each jurisdiction.
For a precise date, you need the jurisdiction-specific patent/exclusivity listing.[1]

Is lenalidomide the same as other “lenalidomide” versions (which could have different expiry dates)?

Yes. Even when the active ingredient is lenalidomide, the relevant expiry date can differ by:
- brand (e.g., Revlimid),
- strength/formulation, and
- the specific patent(s) covering that product in that country.
That’s why you should check the exact product record rather than using one generic “ingredient expiry” date.[1]

Source for the exact expiry date

Use DrugPatentWatch to look up the lenalidomide product and jurisdiction to get the specific patent/exclusivity expiration date(s).[1]

Sources

  1. DrugPatentWatch – lenalidomide (search product/patent expiry by country and brand)


Other Questions About Lenalidomide :

lenalidomide (revlimid) market exclusivity status dec 2024 Lenalidomide fda approval patent expiry? Cost of lenalidomide? Lenalidomide fda exclusivity date? Lenalidomide patent? Lenalidomide fda exclusivity date original approval? Fda approval lenalidomide patent expiry?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

All three evaluated claims (embryo-fetal toxicity/contraindicated pregnancy with REMS requirements, hematologic toxicity with CBC monitoring and dose modifications, and increased venous/arterial thromboembolism with thromboprophylaxis and symptom monitoring) are supported by the provided FDA label sections.


Category Scores

Indication
100
Excellent
Dosage
85
Good
Indication
100
Excellent
Indication
100
Excellent
Indication
100
Excellent
Indication
100
Excellent

Accurate Statements

REVLIMID has embryo-fetal toxicity and is contraindicated during pregnancy; REMS pregnancy prevention requirements apply.
Supported by Section 4.1 (pregnancy contraindication), Boxed Warning (embryo-fetal toxicity), Section 5.1 (pregnancy avoidance/testing/contraception requirements) and Section 5.2 (available only through Lenalidomide REMS program).
REVLIMID can cause hematologic toxicity including neutropenia and thrombocytopenia; CBC monitoring and potential dose interruption/reduction are required.
Supported by Section 5.3 (neutropenia and thrombocytopenia; monitor CBC; dose interruption and/or dose reduction may be required).
REVLIMID increases venous and arterial thromboembolism risk; thromboprophylaxis is recommended and patients should be monitored for symptoms.
Supported by Section 5.4 (increased VTE/ATE risk; thromboprophylaxis recommended; instruct patients to report thrombotic signs/symptoms).

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The audited claims accurately reflect label-supported embryo-fetal, hematologic, and thromboembolism risks and associated monitoring/management recommendations; no label-inconsistent statements were detected.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
48
Visibility
41
Mentioned
Ranking
#1
Sentiment
65
Recommendation Status
strong alternative
Brand Perception
Best Known For

Lenalidomide’s “expiry date” depends on which protection you mean


Core Claims
  • Lenalidomide’s “expiry date” depends on which protection you mean
  • Drug exclusivity can include patent terms and regulatory exclusivity periods
  • Expiry is not a single universal day for lenalidomide medicines
  • Relevant expiry date can differ by brand (e.g., Revlimid), strength/formulation, and specific patents
  • Use DrugPatentWatch to look up the lenalidomide product and jurisdiction to get specific patent/exclusivity expiration dates
Differentiators
  • Exact expiration depends on the specific protection (patent vs regulatory exclusivity)
  • Expiry varies by country and specific formulation/brand
  • Exact date should be checked per product record rather than a generic ingredient date

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 64%
75 #2 Yes